- •Pneumonitis can occur following treatment with the monoclonal antibody alemtuzumab in a patient with multiple sclerosis.
- •In a patient presenting with breathlessness post alemtuzumab infusion a non-infectious cause needs to be considered.
- •Pneumonitis secondary to alemtuzumab can potentially be managed with oral steroids alone.
The most common adverse events associated with the monoclonal antibody alemtuzumab are infusion associated reactions and secondary autoimmune disease. Respiratory complications are unusual following treatment with alemtuzumab, but can be precipitated by an infectious cause. We describe a case of a sub-acute steroid responsive non-infectious pneumonitis affecting a 51 year old woman, who presented one month after initiation of therapy for multiple sclerosis with alemtuzumab.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab.JAMA Neurol. 2017; 74: 961-969
- Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis.J. Neurol. 2017; 264: 168-169
- Alemtuzumab therapy for multiple sclerosis.Neurotherapeutics. 2013; 10: 29-33
- Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings.Neurology. 2017; 89: 1117-1126
- A fatal case of alemtuzumab-associated interstitial pneumonitis.Am. J. Ther. 2008; 15: 82-84
- Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.Mult. Scler. 2015; 21: 22-34
- Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.Immunology. 2009; 128: 260-270
- Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation.Proc. Natl. Acad. Sci. USA. 2013; 110: 20200-20205
- The danger model: a renewed sense of self.Science. 2002; 296: 301-305
- Resident memory T cells (T(RM)) are abundant in human lung: diversity, function, and antigen specificity.PLoS One. 2011; 6: e16245
- Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis.Mult. Scler. 2017; 23: 872-874
- Diffuse Alveolar haemorrhage: a fatal complication after alemtuzumab induction therapy in renal transplantation.Transplant. Proc. 2015; 47: 151-154
- Alemtuzumab for multiple sclerosis: long term follow-up in a multi-centre cohort.Mult. Scler. 2016; 22: 1215-1223
- Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.Mult. Scler. Relat. Disord. 2017; 14: 1-3
- Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.J. Immunol. 2013; 191: 5867-5874
Published online: April 03, 2018
Accepted: April 2, 2018
Received in revised form: March 5, 2018
Received: January 17, 2018
© 2018 Elsevier B.V. All rights reserved.